Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer

Irinotecan and bevacizumab has activity in heavily pre-treated patients with recurrent ovarian cancer, including those with prior bevacizumab and topoisomerase inhibitor use.